TransMedics Group Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group or view top-rated stocks.

Wall Street analysts have given TransMedics Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TransMedics Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

TransMedics Group saw a decline in short interest in July. As of July 15th, there was short interest totaling 1,320,000 shares, a decline of 14.3% from the June 30th total of 1,540,000 shares. Based on an average daily trading volume, of 382,800 shares, the short-interest ratio is presently 3.4 days. Currently, 5.3% of the shares of the stock are short sold.
View TransMedics Group's Short Interest.

TransMedics Group is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for TransMedics Group.

TransMedics Group will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. The company earned $7.05 million during the quarter, compared to analyst estimates of $6.93 million. TransMedics Group had a negative trailing twelve-month return on equity of 26.18% and a negative net margin of 110.54%.
View TransMedics Group's earnings history.

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TMDX stock has increased by 114.8% and is now trading at $29.25.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued 1-year price objectives for TransMedics Group's shares. Their forecasts range from $15.00 to $79.00. On average, they anticipate TransMedics Group's stock price to reach $45.40 in the next year. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for TransMedics Group or view top-rated stocks among Wall Street analysts.

17 employees have rated TransMedics Group CEO Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

Some companies that are related to TransMedics Group include Outset Medical (OM), BioLife Solutions (BLFS), ViewRay (VRAY), Cutera (CUTR), Natus Medical (NTUS), AxoGen (AXGN), Semler Scientific (SMLR), Stereotaxis (STXS), Zynex (ZYXI), Edap Tms (EDAP), Second Sight Medical Products (EYES), Movano (MOVE), Yubo International Biotech (YBGJ), FONAR (FONR) and BioSig Technologies (BSGM).
View all of TMDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and The Walt Disney (DIS).

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMDX stock can currently be purchased for approximately $29.25.

TransMedics Group has a market capitalization of $808.00 million and generates $25.64 million in revenue each year. The company earns $-28,750,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

TransMedics Group employs 110 workers across the globe.

The official website for TransMedics Group is www.transmedics.com.

TransMedics Group is headquartered at 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]